Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. MediPharm Labs Corp.
  6. Summary
    LABS   CA58504D1006

MEDIPHARM LABS CORP.

(LABS)
  Report
Delayed Quote. Delayed Toronto Stock Exchange - 05/16 03:59:59 pm
0.09 CAD   +12.50%
05/16TRANSCRIPT : MediPharm Labs Corp., Q1 2022 Earnings Call, May 16, 2022
CI
05/16MediPharm Labs Posts Q1 Net loss Near $7.5 Million
MT
05/16MediPharm Labs Reports First Quarter Results
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
05/10/2022 05/11/2022 05/12/2022 05/13/2022 05/16/2022 Date
0.095(c) 0.095(c) 0.09(c) 0.08(c) 0.09(c) Last
1 008 835 349 348 1 535 645 2 962 107 1 088 358 Volume
-9.52% 0.00% -5.26% -11.11% +12.50% Change
More quotes
Estimated financial data (e)
Sales 2022 33,3 M 25,8 M 25,8 M
Net income 2022 -23,0 M -17,8 M -17,8 M
Net Debt 2022 - - -
P/E ratio 2022 -1,17x
Yield 2022 -
Sales 2023 43,9 M 34,0 M 34,0 M
Net income 2023 -17,1 M -13,3 M -13,3 M
Net Debt 2023 - - -
P/E ratio 2023 -1,80x
Yield 2023 -
Capitalization 24,7 M 19,1 M 19,1 M
Capi. / Sales 2022 0,74x
Capi. / Sales 2023 0,56x
Nbr of Employees 190
Free-Float 93,7%
More Financials
Company
MediPharm Labs Corp. is a Canada-based pharmaceutical company that is specialized in cannabis. The Company produces purified, pharmaceutical-like cannabis extracts and related derivative products. The Company formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its... 
Read more
Sector
Pharmaceuticals
Calendar
06/30Shareholder meeting
More about the company
Ratings of MediPharm Labs Corp.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about MEDIPHARM LABS CORP.
05/16TRANSCRIPT : MediPharm Labs Corp., Q1 2022 Earnings Call, May 16, 2022
CI
05/16MediPharm Labs Posts Q1 Net loss Near $7.5 Million
MT
05/16MediPharm Labs Reports First Quarter Results
PR
05/16NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
05/13NORTH AMERICAN MORNING BRIEFING : Tech Futures -2-
DJ
05/12MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results
AQ
04/20MediPharm Labs Names Experienced Pharma and Med Tech Executive David Pidduck, as CEO
PR
04/20MediPharm Labs Corp. Announces CEO Changes
CI
04/20MediPharm Labs Corp. Announces Management Changes
CI
04/08Most actively traded companies on the Toronto Stock Exchange
AQ
04/06MediPharm Labs Continues to Lead with Innovation, Launches CBG and Water-Soluble Produc..
AQ
04/05MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Produ..
AQ
04/05Medipharm Labs Corp Launches CBG and Water-Soluble Products
CI
04/01TRANSCRIPT : MediPharm Labs Corp., Q4 2021 Earnings Call, Apr 01, 2022
CI
03/31MEDIPHARM LABS BRIEF : Warren Everitt and MediPharm Labs Have Mutually Agreed to End the R..
MT
More news
News in other languages on MEDIPHARM LABS CORP.
05/16MediPharm Labs affiche une perte nette de près de 7,5 millions de dollars au premier tr..
04/20MediPharm Labs Corp. annonce des changements de PDG
04/20MediPharm Labs Corp. annonce des changements de direction
04/05Medipharm Labs Corp lance des produits CBG et hydrosolubles
03/31MediPharm Labs Corp. annonce ses résultats pour l'année complète se terminant le 31 déc..
More news
Chart MEDIPHARM LABS CORP.
Duration : Period :
MediPharm Labs Corp. Technical Analysis Chart | LABS | CA58504D1006 | MarketScreener
Technical analysis trends MEDIPHARM LABS CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 0,09 CAD
Average target price 0,25 CAD
Spread / Average Target 178%
EPS Revisions
Managers and Directors
David A. Pidduck Chief Executive Officer & Director
Keith Strachan President
Greg Hunter Chief Financial Officer
Chris Taves Chairman
Ina Shira Dubinsky Lead Scientist-Secondary Processing
Sector and Competitors
1st jan.Capi. (M$)
MEDIPHARM LABS CORP.-51.35%17
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.26.07%6 412
DONG-E-E-JIAO CO.,LTD.-36.00%3 045
TASLY PHARMACEUTICAL GROUP CO., LTD-31.92%2 404
CANOPY GROWTH CORPORATION-30.98%2 323
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK6.94%1 896